Alliqua has just successfully passed yet another milestone in...

Alliqua has just successfully passed yet another milestone in developing a hydrogel based transdermal patch to target pain treatment in PHN or shingles.


Their hydrogel technology is based on electrolytes which allow to control the conductive properties of the gel.
These electron-beam cross-linked sheet gels can be linked to many varied substrates.
The polymer water mixes are exposed to electron beams and create a water sheet.
They just finalised a comparative in vitro study ( see our Azopharma study over a year ago which was paid by our original FMCG ).

In the in vitro permeation study, multiple formulations were evaluated, with some achieving mean cumulative drug-permeation amounts much higher than the market leading product, indicating the potential for an improvement over the existing product.


Sounds just similar to our in vitro patch results independently verified by Azopharma.
Their products are also easy and cheap to produce, have little or no skin irritability and excellent permeability.
Sounds all familiar, doesnt it?


What those news are telling me is that transdermal pain patches are the way of the future, otherwise not several companies would simultaneously pursue the idea.
It also tells me that electron based systems are increasingly showing promise.
Finally, we are more than a year ahead of this company as our first in vivo test results already confirmed our excellent in vitro testing and strong competitiveness within the market.


http://www.drugdeliverytech.com/ME2/dirmod.asp?sid=&nm=&type=news&mod=News&mid=9A02E3B96F2A415ABC72CB5F516B4C10&tier=3&nid=68CE5A109C724EDB86F0E3EA118B544D

http://alliqua.com/